TheraRadar
← Back
Data updated: Jun 28, 2026

COASTAL PHARMS

Generics

COASTAL PHARMS is a generic drug manufacturer focused on Ophthalmology.

2011
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

COASTAL PHARMS's Key Drugs

COASTAL PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

COASTAL PHARMS's Recent FDA Approvals

New NDA/BLA approvals for COASTAL PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

COASTAL PHARMS's Therapeutic Areas

COASTAL PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Ophthalmology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Ophthalmology 100%
1 drugs

COASTAL PHARMS's Top Competitors

COASTAL PHARMS's closest competitors by therapeutic-area and drug-target overlap include Novartis, AbbVie, and OTSUKA ICU MEDCL. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

COASTAL PHARMS Pipeline Snapshot

Active clinical trials for COASTAL PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Ophthalmology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling